
News|Articles|February 1, 2008
FDA Pipeline Preview, February 2008
FDA-related information through February 2008 on Fluvoxamine extended-release capsules, dalbavancin, bazedoxifene, HPV vaccine (Cervarix), valrubicin, motexafin gadolinium, COL-003, CDX-110, sugammadex, mecaserim rinfabate, A-001, beclomethasone, clobazam, fludarabine tablets, JZP-8, and AST-120
Advertisement
Approvable designations
Complete response letter
Nonapprovable designations
Fast-track designations
Priority review
Orphan drug designations
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Sanofi acquires Dynavax for $2.2 billion to bolster vaccine portfolio
2
Patients may not see savings from new Medicare drug programs
3
FDA accepts NDA for gedatolisib, Celcuity’s investigational breast cancer treatment
4
Why Timing, Access and Interpretation Matter in Oncology Biomarker Testing
5




















































